Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital in Boston said patients ask her about microdosing "all the time." "(But) there are no studies showing what it does," she cautioned in a TODAY segment that aired on Nov
NICE recommend tirzepatide and semaglutide for patients with at least one weight-related comorbidity and a BMI 35 kg/m 2 (or BMI 30 kg/m 2 and who meet the criteria for referral to specialist weight management services, for semaglutide only) and liraglutide for patients with a BMI 35 kg/m 2 , non-diabetic hyperglycaemia, and a high risk of cardiovascular disease
However, human clinical trials remain scarce
CORRECTION (Oct
Roughly 33% of them exhibited positive clinical results as compared to 8.5% in the placebo group, and the researchers reported significantly greater intercourse satisfaction than those in the [latter].14 A more recent, albeit more scope-limited, study broadly corroborates the 2008 outcomes
DOI:10.1007/s11033-014-3254-y [ Links ] 50